Fractyl Health (GUTS) Q4 2025 earnings summary

Executive summary

• Revita, an endoscopic procedure for post-GLP-1 weight maintenance, is advancing with strong clinical and regulatory momentum, targeting patients discontinuing GLP-1 therapy who face rapid weight regain.

• Six-month data from the REMAIN-1 midpoint cohort clarified optimal patient selection and procedural parameters, strengthening confidence in pivotal study design and commercial prospects.

• The pivotal REMAIN-1 study is fully enrolled, with over 300 participants, and is the largest sham-controlled GI endoscopy pivotal trial to date; randomization completed with topline 6-month data expected early Q4 2026.

• Favorable FDA feedback supports a de novo pathway, expediting regulatory and commercial timelines, with submission planned for late Q4 2026.

• New post-hoc analyses show a dose-dependent treatment effect for Revita in post-GLP-1 weight maintenance.

Financial highlights

• Q4 2025 R&D expenses were $16.5M, down from $20.3M in Q4 2024, due to strategic reprioritization and pausing of Revitalize-1.

• SG&A expenses rose to $6.8M from $4.9M, mainly due to underwriter commissions from August 2025 financing.

• Net loss for Q4 2025 was $43.7M, up from $25M, driven by a $20.2M non-cash warrant liability adjustment.

• Adjusted EBITDA improved to -$21.2M from -$22.1M year-over-year.

• Cash and equivalents stood at $81.5M at year-end, with an additional $4.1M from warrant exercises in January 2026.

Outlook and guidance

• Current cash position funds operations into early 2027, covering pivotal data readout and potential de novo submission.

• No plans for incremental capital raise before pivotal data; ATM facility closed.

• Key catalysts in 2026 include one-year REVEAL-1 and REMAIN-1 data, six-month pivotal data in early Q4, and de novo submission in late Q4.

• Anticipated first-in-human dosing for RJVA-001 gene therapy in H2 2026, pending regulatory feedback.